AR031924A1 - ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE - Google Patents
ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESEInfo
- Publication number
- AR031924A1 AR031924A1 ARP010105828A ARP010105828A AR031924A1 AR 031924 A1 AR031924 A1 AR 031924A1 AR P010105828 A ARP010105828 A AR P010105828A AR P010105828 A ARP010105828 A AR P010105828A AR 031924 A1 AR031924 A1 AR 031924A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- silenced
- methods
- tissues
- defective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invencion provee anticuerpos anti-CD28 que son defectuosos en actividad mitogeno (anticuerpos anti-CD28 silenciados), métodos para producir dichos anticuerpos, composiciones que contienen anticuerpos y métodos de inmunosupresion, inducen tolerancia de células T y tratan rechazos de transplantes de organos y/o tejidosThe present invention provides anti-CD28 antibodies that are defective in mitogenic activity (silenced anti-CD28 antibodies), methods for producing said antibodies, compositions containing antibodies and immunosuppression methods, induce tolerance of T cells and treat organ transplant rejections and / or tissues
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25515500P | 2000-12-14 | 2000-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031924A1 true AR031924A1 (en) | 2003-10-08 |
Family
ID=22967074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105828A AR031924A1 (en) | 2000-12-14 | 2001-12-14 | ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1341553A4 (en) |
| JP (1) | JP2004515243A (en) |
| KR (1) | KR20040020866A (en) |
| CN (1) | CN1272345C (en) |
| AR (1) | AR031924A1 (en) |
| AU (2) | AU2608602A (en) |
| BR (1) | BR0116686A (en) |
| CA (1) | CA2432736A1 (en) |
| CZ (1) | CZ20031909A3 (en) |
| HU (1) | HUP0400697A3 (en) |
| IL (1) | IL156262A0 (en) |
| MX (1) | MXPA03005327A (en) |
| NO (1) | NO20032542L (en) |
| NZ (1) | NZ526569A (en) |
| PL (1) | PL363239A1 (en) |
| RU (1) | RU2261723C2 (en) |
| WO (1) | WO2002047721A1 (en) |
| ZA (1) | ZA200305384B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002066059A2 (en) | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc | Agents that specifically block cd28-mediated signaling and uses therefor |
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
| FR2951176A1 (en) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR |
| PL2536764T3 (en) * | 2010-02-18 | 2018-12-31 | Ose Immunotherapeutics | Anti-cd28 humanized antibodies |
| CN114917185B (en) | 2016-10-21 | 2023-11-14 | 美国安进公司 | Pharmaceutical formulations and methods of making the same |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN113692286A (en) * | 2019-03-14 | 2021-11-23 | 比昂生物制剂公司 | A method for immunosuppression |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023532339A (en) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | Viruses engineered to promote sanotransmission and their use in treating cancer |
| KR20230166150A (en) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | Anti-cd28 compositions |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024148336A1 (en) * | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
-
2001
- 2001-12-14 AR ARP010105828A patent/AR031924A1/en unknown
- 2001-12-14 AU AU2608602A patent/AU2608602A/en active Pending
- 2001-12-14 BR BR0116686-7A patent/BR0116686A/en not_active IP Right Cessation
- 2001-12-14 AU AU2002226086A patent/AU2002226086C1/en not_active Ceased
- 2001-12-14 RU RU2003121231/15A patent/RU2261723C2/en not_active IP Right Cessation
- 2001-12-14 KR KR10-2003-7007798A patent/KR20040020866A/en not_active Application Discontinuation
- 2001-12-14 PL PL01363239A patent/PL363239A1/en not_active Application Discontinuation
- 2001-12-14 WO PCT/US2001/047955 patent/WO2002047721A1/en not_active Application Discontinuation
- 2001-12-14 HU HU0400697A patent/HUP0400697A3/en unknown
- 2001-12-14 EP EP01995504A patent/EP1341553A4/en not_active Withdrawn
- 2001-12-14 JP JP2002549291A patent/JP2004515243A/en not_active Withdrawn
- 2001-12-14 CA CA002432736A patent/CA2432736A1/en not_active Abandoned
- 2001-12-14 CZ CZ20031909A patent/CZ20031909A3/en unknown
- 2001-12-14 MX MXPA03005327A patent/MXPA03005327A/en unknown
- 2001-12-14 NZ NZ526569A patent/NZ526569A/en unknown
- 2001-12-14 CN CNB018226361A patent/CN1272345C/en not_active Expired - Fee Related
- 2001-12-14 IL IL15626201A patent/IL156262A0/en unknown
-
2003
- 2003-06-05 NO NO20032542A patent/NO20032542L/en not_active Application Discontinuation
- 2003-07-11 ZA ZA200305384A patent/ZA200305384B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03005327A (en) | 2004-12-03 |
| CN1489473A (en) | 2004-04-14 |
| ZA200305384B (en) | 2004-10-11 |
| HUP0400697A3 (en) | 2007-05-02 |
| AU2608602A (en) | 2002-06-24 |
| RU2003121231A (en) | 2005-02-10 |
| WO2002047721A1 (en) | 2002-06-20 |
| JP2004515243A (en) | 2004-05-27 |
| PL363239A1 (en) | 2004-11-15 |
| CN1272345C (en) | 2006-08-30 |
| EP1341553A4 (en) | 2004-07-28 |
| IL156262A0 (en) | 2004-01-04 |
| AU2002226086B2 (en) | 2005-08-25 |
| CZ20031909A3 (en) | 2003-11-12 |
| NO20032542L (en) | 2003-08-07 |
| EP1341553A1 (en) | 2003-09-10 |
| NO20032542D0 (en) | 2003-06-05 |
| BR0116686A (en) | 2003-12-30 |
| CA2432736A1 (en) | 2002-06-20 |
| HUP0400697A2 (en) | 2004-06-28 |
| AU2002226086C1 (en) | 2006-03-09 |
| KR20040020866A (en) | 2004-03-09 |
| RU2261723C2 (en) | 2005-10-10 |
| NZ526569A (en) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031924A1 (en) | ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE | |
| MX2009003588A (en) | Human placental collagen compositions, and methods of making and using the same. | |
| ES2183937T3 (en) | INHIBITORS OF THE CELL ADHESION. | |
| UY24256A1 (en) | SPECIFIC MONOCLONAL MONO ANTIBODIES FOR HUMAN B 7.1 AND / OR B7.2 ANTIBODIES, PRIMATIZED FORMS OF THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME AS IMMUNOSUPPRESSORS | |
| BR0114630A (en) | Growth Hormone Secretagogues | |
| ECSP045520A (en) | TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS | |
| GT200300031A (en) | SUBSTITUTE INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE | |
| CY1109413T1 (en) | METHODS OF TREATMENT OF MULTIPLE MYELOMA AND BACKGROUND OF BONE REPLACEMENT BY USING INTEGRE | |
| BR0214029A (en) | Methods and compositions for using stromal cells to support embryonic and adult stem cells | |
| BR0210593A (en) | defensin polynucleotides and methods of use | |
| AR023463A1 (en) | USE OF AZETIDINONE COMPOUNDS | |
| BRPI0607883A2 (en) | method for obtaining readily available peripheral blood derived cellular material and a composition of said cellular material | |
| ECSP045146A (en) | SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
| BR0210599A (en) | Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| ECSP034924A (en) | Substituted derivatives of 1-oxa-2,8-daza-spiro [4,5] dec-2-eno | |
| BRPI0607504A2 (en) | pig population having low levels of endogenous retroviruses and their uses | |
| BR0307629A (en) | Methods and compositions for treating hyperproliferative conditions | |
| GT200300046A (en) | INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE | |
| HK1205531A1 (en) | Mesenchymal stem cells and uses therefor | |
| BR0314369A (en) | Methods for inhibiting cell growth, for inducing cell death of a cancer cell, for treating or preventing cancer in an individual, and for identifying an agent that inhibits cancerous growth of a purified ephb4 cell, agent, and antibody. | |
| DE69721021D1 (en) | BUBBLE MUKOSA WITH CELLS FOR TISSUE RECONSTRUCTION | |
| WO2007002469A3 (en) | Therapeutic compositions and methods using transforming growth factor-beta mimics | |
| CO2024005352A2 (en) | Oligonucleotide compositions and methods thereof | |
| AR029624A1 (en) | ANTIBODIES OR FRAGMENTS OF RECOMBINANT ANTI-IDIOTIPIC ANTIBODIES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |